ArticleAlzheimer's research & therapy2023
Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach.
Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Neuropsychological Diagnostic Tools in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.Aging and disease · 2025Pooled it
- Article
- Outcomes reported in interventional studies for mild cognitive impairment: a scoping umbrella review to inform core outcome set development.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- APOE ε4-related structural vulnerability in mild cognitive impairment: a subsystem-based analysis of the default mode network.Research square · 2026Article
- Explainable Machine Learning Reveals Time-Dependent Cognitive Risk in Minor Neurocognitive Disorder: Implications for Health Promotion and Early Risk Stratification.Biomedicines · 2026Article
- Social determinants of brain structure and cognition.Social science & medicine (1982) · 2026Article
- A Two-Stage Framework for Early Detection and Subtype Identification of Alzheimer's Disease Through Multimodal Biomarker Extraction and Improved GCN.Brain sciences · 2026Article
- Biomarker-integrated prognostic stagings for Alzheimer's Disease.Nature communications · 2026Article
- Risk Factors and Annual Rates of Cognitive Decline in Elderly Mild Cognitive Impairment: A Retrospective Cohort Study.Neuropsychiatric disease and treatment · 2026Article
- Data-driven subtypes of mild cognitive impairment and their modifiable determinants: latent profile analysis of the BIOCIS cohort.NPJ dementia · 2026Article
- Data-driven subtypes of subjective cognitive decline: neuropsychological profiles, Alzheimer's disease biomarkers, and clinical trajectories.Journal of neurology · 2025Article
- The impact of lifestyle factors on trajectories of cognitive subtypes in the older adult population.Scientific reports · 2025Article
- Cognitive and neuropsychological trajectories in patients with mixed neurodegenerative pathologies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Sex-specific association of depressive symptom trajectories with cognitive decline and clinical progression in mild cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Revealing heterogeneity in mild cognitive impairment based on individualized structural covariance network.Alzheimer's research & therapy · 2025Article
- Sleep trajectories across three cognitive-aging pathways in community older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Mixture Disease Progression Model to Predict and Cluster the Long-Term Trajectory of Cognitive Decline in Alzheimer's Disease.Therapeutic innovation & regulatory science · 2025Article
- Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.Molecular psychiatry · 2025Article
- Developing a core outcome set for interventions in people with mild cognitive impairment: study protocol.BMJ open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGiven the complex and progressive nature of mild cognitive impairment (MCI), the ability to delineate and understand the heterogeneous cognitive trajectories is crucial for developing personalized medicine and informing trial design. The primary goals of this study were to examine whether different cognitive trajectories can be identified within subjects with MCI and, if present, to characterize each trajectory in relation to changes in all major Alzheimer's disease (AD) biomarkers over time.
methodsIndividuals with a diagnosis of MCI at the first visit and ≥ 1 follow-up cognitive assessment were selected from the Alzheimer's Disease Neuroimaging Initiative database (n = 936; age 73 ± 8; 40% female; 16 ± 3 years of education; 50% APOE4 carriers). Based on the Alzheimer's Disease Assessment Scale-Cognitive Subscale-13 (ADAS-Cog-13) total scores from baseline up to 5 years follow-up, a non-parametric k-means longitudinal clustering method was performed to obtain clusters of individuals with similar patterns of cognitive decline. We further conducted a series of linear mixed-effects models to study the associations of cluster membership with longitudinal changes in other cognitive measures, neurodegeneration, and in vivo AD pathologies.
resultsFour distinct cognitive trajectories emerged. Cluster 1 consisted of 255 individuals (27%) with a nearly non-existent rate of change in the ADAS-Cog-13 over 5 years of follow-up and a healthy-looking biomarker profile. Individuals in the cluster 2 (n = 336, 35%) and 3 (n = 240, 26%) groups showed relatively mild and moderate cognitive decline trajectories, respectively. Cluster 4, comprising about 11% of our study sample (n = 105), exhibited an aggressive cognitive decline trajectory and was characterized by a pronouncedly abnormal biomarker profile.
conclusionsIndividuals with MCI show substantial heterogeneity in cognitive decline. Our findings may potentially contribute to improved trial design and patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.